Skip to main content
. 2021 May 20;6:75. doi: 10.1038/s41541-021-00334-3

Fig. 3. Alum/CpG/DP7-based vaccines suppressed tumor progression in multiple models.

Fig. 3

a Schedules of vaccine immunization in the prophylactic models. In the prophylactic models, mice were treated with the indicated vaccines (on days 0, 14, and 28) and then challenged s.c. with 2 × 105 NY-ESO-1-B16 (c) or 2 × 106 E.G7-OVA (e) cells on day 35 according to the schedules. The tumor volume was measured every 3 days. b Schedules of vaccine immunization in the therapeutic models. In the therapeutic models, mice were challenged s.c. with 2 × 105 NY-ESO-1-B16, (d) 2 × 106 E.G7-OVA (f), or 2 × 105 NY-ESO-1-4T1 (g) cells on day 0 and then treated with the indicated vaccines (on days 5, 12, and 19) according to the schedules. The tumor volume was measured every 3 days. N = 10/group. Bars represent means and SEM. *P < 0.05, **P < 0.01, ***P < 0.001.